You have free access to this content

Cancer

Cover image for Cancer

1 October 2005

Volume 104, Issue 7

Pages 1335–1557

  1. Original Articles

    1. Top of page
    2. Original Articles
    3. Original Article
    4. Original Articles
    5. Correspondence
    1. Disease Site

      Breast Disease
      You have free access to this content
      New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma : A pooled analysis of the randomized trials (pages 1335–1342)

      Paolo Carlini, Emilio Bria, Diana Giannarelli, Gianluigi Ferretti, Alessandra Felici, Paola Papaldo, Alessandra Fabi, Cecilia Nisticò, Serena Di Cosimo, Enzo Maria Ruggeri, Michele Milella, Marcella Mottolese, Edmondo Terzoli and Francesco Cognetti

      Article first published online: 8 AUG 2005 | DOI: 10.1002/cncr.21339

      The authors performed a pooled analysis including all the Phase III trials published between 1996 and 2004 evaluating the aromatase inhibitors (AI) approved or not by the Food and Drug Administration and the European Agency for the Evaluation of Medical Products as second-line endocrine therapy for patients with metastatic breast carcinoma. No significant differences in overall response rate and time to disease progression were seen in the whole group of 9 trials comparing AI with megestrol acetate (MEG) (3908 patients) and in the 6 trials including nonsteroidal AI versus MEG (2415 patients). AI significantly yielded more hot flashes than MEG but caused significantly less toxicity than MEG in weight gain, dyspnea, and peripheral edema.

    2. You have free access to this content
      Investigating the correlation between hospital of primary treatment and the survival of women with breast cancer (pages 1343–1348)

      Nicole Hébert-Croteau, Jacques Brisson, Jacques Lemaire, Jean Latreille and Raynald Pineault

      Article first published online: 3 AUG 2005 | DOI: 10.1002/cncr.21336

      The hospital annual breast cancer caseload was a significant determinant of survival in a population-based cohort of 1727 women with lymph node-negative breast cancer from Quebec, Canada, after characteristics of the patient and the attending physician were taken into account. However, this correlation was not independent and disappeared when the type of hospital, defined by features like research and teaching activities or on-site availability of radiation therapy, which we assumed were related to proficiency of care, also were taken into account.

    3. Gastrointestinal Tract
      You have free access to this content
      Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus (pages 1349–1355)

      Pooja R. Rohatgi, Stephen G. Swisher, Arlene M. Correa, Tsung T. Wu, Zhongxing Liao, Ritsuko Komaki, Garrett Walsh, Ara Vaporciyan, Patrick M. Lynch, David C. Rice, Jack A. Roth and Jaffer A. Ajani

      Article first published online: 29 AUG 2005 | DOI: 10.1002/cncr.21346

      In the current study, the authors analyzed several clinical characteristics of patients with carcinoma of the esophagus who were undergoing preoperative chemoradiotherapy to determine whether patterns of failure are correlated with the degree of residual carcinoma after preoperative chemoradiotherapy. The patterns of distant metastases correlated with the degree of response to chemoradiation.

    4. You have free access to this content
      Colorectal carcinoma screening procedure use among primary care patients (pages 1356–1361)

      Jennifer Elston Lafata, L. Keoki Williams, Tamir Ben-Menachem, Christina Moon and George Divine

      Article first published online: 9 AUG 2005 | DOI: 10.1002/cncr.21333

      Slightly more than one-half of insured, primary care patients (54%) received evidence-based recommended colorectal carcinoma screening procedures within a recent 5-year period. Although colonoscopy use increased over the period, overall annual screening procedure use increased by only 3%. Despite a positive relation between the frequency of health maintenance examinations and screening procedure use, the majority of unscreened patients (64%) had at least 3 routine health maintenance examinations during the 5 years. The authors found that there are significant opportunities to increase colorectal carcinoma screening among primary care patients.

    5. Genitourinary Disease
      You have free access to this content
      Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy : A Multicenter European Study (pages 1362–1371)

      Luca Cindolo, Jean-Jacques Patard, Paolo Chiodini, Luigi Schips, Vincenzo Ficarra, Jacques Tostain, Alexandre de La Taille, Vincenzo Altieri, Bernard Lobel, Richard E. Zigeuner, Walter Artibani, François Guillé, Claude C. Abbou, Luigi Salzano and Ciro Gallo

      Article first published online: 22 AUG 2005 | DOI: 10.1002/cncr.21331

      The current study better defined the general applicability of prognostic models for predicting survival in patients with nonmetastatic renal cell carcinoma treated with nephrectomy. The results suggested that postoperative models discriminate substantially better than preoperative models.

    6. You have free access to this content
      Impact of brachytherapy on regional, racial, marital status, and age-related patterns of definitive treatment for clinically localized prostate carcinoma (pages 1372–1380)

      Laurel A. Copeland, Mohamed A. Elshaikh, James Jackson, Louis A. Penner and Willie Underwood III

      Article first published online: 23 AUG 2005 | DOI: 10.1002/cncr.21341

      Permanent prostate brachytherapy appears to be replacing other treatment modalities in increasing numbers of clinically localized prostate carcinoma cases. Persistent regional, racial/ethnic, marital status, and age-related differences in the use of permanent prostate brachytherapy merit further investigation.

    7. You have free access to this content
      Treatment decision-making strategies and influences in patients with localized prostate carcinoma (pages 1381–1390)

      Clement K. Gwede, Julio Pow-Sang, John Seigne, Randy Heysek, Mohamed Helal, Kristin Shade, Alan Cantor and Paul B. Jacobsen

      Article first published online: 3 AUG 2005 | DOI: 10.1002/cncr.21330

      In general, patients chose brachytherapy because of quality of life considerations and because they believed more strongly that this treatment was the least invasive, and they wanted to avoid surgery. In contrast, “cure” and complete removal of the tumor were the main motivations for patients selecting radical prostatectomy. Approximately half of the patients reported difficulty (49%) and distress (45%) while making treatment decision, but no regrets (74%) regarding the treatment choice they made. Long-term data are needed to evaluate distress and decisional regret as patients experience treatment-related chronic side effects and efficacy outcomes.

    8. Gynecologic Oncology
      You have free access to this content
      Amplification of c-erbB2 oncogene : A major prognostic indicator in uterine serous papillary carcinoma (pages 1391–1397)

      Alessandro D. Santin, Stefania Bellone, Sue Van Stedum, Wendy Bushen, Michela Palmieri, Eric R. Siegel, Luis E. De Las Casas, Juan J. Roman, Alexander Burnett and Sergio Pecorelli

      Article first published online: 22 AUG 2005 | DOI: 10.1002/cncr.21308

      The HER-2/neu oncogene is a major prognostic indicator and a novel therapeutic target in uterine serous papillary carcinoma.

    9. You have free access to this content
      Ovarian cancer: Can we make the clinical diagnosis earlier? (pages 1398–1407)

      Lloyd H. Smith, Cyllene R. Morris, Shagufta Yasmeen, Arti Parikh-Patel, Rosemary D. Cress and Patrick S. Romano

      Article first published online: 22 AUG 2005 | DOI: 10.1002/cncr.21310

      Patients with ovarian cancer often recall having symptoms for months before diagnosis. For this study, the authors used data from the Surveillance, Epidemiology, and End Results-Medicare linkage to provide objective evidence regarding the emergence of symptoms prior to diagnosis.

    10. Head and Neck Disease
      You have free access to this content
      Risk-group definition by recursive partitioning analysis of patients with squamous cell head and neck carcinoma treated with surgery and postoperative radiotherapy (pages 1408–1417)

      Johannes A. Langendijk, Ben J. Slotman, Isaac van der Waal, P. Doornaert, Johannes Berkof and Charles R. Leemans

      Article first published online: 29 AUG 2005 | DOI: 10.1002/cncr.21340

      The authors studied a recursive partitioning analysis classification scheme that allowed for a clear definition of three prognostic groups with regard to locoregional control and overall survival in patients with squamous cell head and neck carcinoma. The prognostic groups defined may be useful in the design of future prospective, randomized studies investigating new treatment modalities.

    11. You have free access to this content
      Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma (pages 1418–1427)

      Philip C. Amrein, John R. Clark, Jeffrey G. Supko, Richard L. Fabian, Chiu C. Wang, A. Dimitrios Colevas, Marshall R. Posner, Daniel G. Deschler, James W. Rocco, Dianne M. Finkelstein and James F. McIntyre

      Article first published online: 22 AUG 2005 | DOI: 10.1002/cncr.21312

      The use of amifostine allowed the authors to administer more paclitaxel concomitantly with radiotherapy in the treatment of patients with advanced head and neck carcinoma, and the schedule yielded an excellent survival rate at 30 months (66%). Pharmacokinetic studies showed that there was no interaction between amifostine and paclitaxel.

    12. Hematologic Malignancies
      You have free access to this content
      Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma (pages 1428–1433)

      Antonio Palumbo, Alessandra Bertola, Pellegrino Musto, Tommaso Caravita, Vincenzo Callea, Martina Nunzi, Mariella Grasso, Patrizia Falco, Clotilde Cangialosi and Mario Boccadoro

      Article first published online: 22 AUG 2005 | DOI: 10.1002/cncr.21342

      No data were available on the association of thalidomide with oral melphalan and prednisone. In the current study, this drug combination induced a fast tumor response with complete disease remission rates similar to those observed after an autologous transplant. Administration of anticoagulants is mandatory to prevent thromboembolism.

    13. You have free access to this content
      Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma (pages 1434–1441)

      Catherine Thieblemont, Daciana Antal, Laurence Lacotte-Thierry, Vincent Delwail, Daniel Espinouse, Anne-Sophie Michallet, Catherine Traulle, Fadhela Bouafia-Sauvy, Christine Giraud, Gilles Salles, François Guilhot and Bertrand Coiffier

      Article first published online: 15 AUG 2005 | DOI: 10.1002/cncr.21313

      In this retrospective analysis, the authors evaluated the efficacy of chemotherapy combined with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantel cell lymphoma (MCL). The combination improved overall survival and progression-free survival in patients with MCL patients without adding toxicities.

    14. You have free access to this content
      Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence (pages 1442–1452)

      Richard A. Larson, Eric L. Sievers, Edward A. Stadtmauer, Bob Löwenberg, Elihu H. Estey, Hervé Dombret, Matthias Theobald, Dimitris Voliotis, John M. Bennett, Maria Richie, Lance H. Leopold, Mark S. Berger, Matthew L. Sherman, Michael R. Loken, Jacques J. M. van Dongen, Irwin D. Bernstein, Frederick R. Appelbaum and Mylotarg Study Group

      Article first published online: 22 AUG 2005 | DOI: 10.1002/cncr.21326

      In a pooled analysis of 3 Phase II, open-label studies of 277 patients with acute myeloid leukemia in first recurrence, gemtuzumab ozogamicin (Mylotarg®) provided a 26% overall remission rate with a generally tolerable adverse event profile. The median overall survival was 4.9 months; however, for patients who achieved remission, the median overall survival was 12.6 months, and the median recurrence-free survival was 5.2 months.

    15. Lung Disease
      You have free access to this content
      Sentinel lymph node mapping and molecular staging in nonsmall cell lung carcinoma (pages 1453–1461)

      Dianne Pulte, Eric Li, Bernard K. Crawford, Elliot Newman, Alice Alexander, David C. Mustalish and Daniel R. Jacobson

      Article first published online: 29 AUG 2005 | DOI: 10.1002/cncr.21325

      Thirteen patients who underwent surgery for lung carcinoma with curative intent also underwent sentinel lymph node (SLN) mapping and molecular staging by reverse transcriptase-polymerase chain reaction analysis, techniques that had not been employed together previously in any malignancy. This approach improved the sensitivity of detecting lymph node micrometastases: Several patients with N0 disease, as determined with routine pathology and immunohistochemistry, were upstaged to molecular Stage N1 or N2. Patients with N0 disease according to molecular staging may be a group with a good prognosis who should be spared the toxicities of adjuvant chemotherapy.

  2. Original Article

    1. Top of page
    2. Original Articles
    3. Original Article
    4. Original Articles
    5. Correspondence
    1. Disease Site

      Melanoma
      You have free access to this content
      Wide excision without radiation for desmoplastic melanoma (pages 1462–1467)

      Alisha Arora, Lori Lowe, Lyndon Su, Riley Rees, Carol Bradford, Vincent C. Cimmino, Alfred E. Chang, Timothy M. Johnson and Michael S. Sabel

      Article first published online: 3 AUG 2005 | DOI: 10.1002/cncr.21311

      Adjuvant radiation has been proposed for patients with desmoplastic melanoma, who reportedly have local recurrence rates as high as 40–60%. In this retrospective review of 65 patients with pure desmoplastic melanoma, the results suggested that wide local excision, with careful attention to appropriate margins, produces excellent local control rates without the need for adjuvant radiation.

  3. Original Articles

    1. Top of page
    2. Original Articles
    3. Original Article
    4. Original Articles
    5. Correspondence
    1. Disease Site

      Neuro-Oncology
      You have free access to this content
      The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors (pages 1468–1477)

      J. Matthew McDonald, Siew Ju See, Ivo W. Tremont, Howard Colman, Mark R. Gilbert, Morris Groves, Peter C. Burger, David N. Louis, Caterina Giannini, Gregory Fuller, Sandra Passe, Hilary Blair, Robert B. Jenkins, Helen Yang, Alicia Ledoux, Joann Aaron, Ulka Tipnis, Wei Zhang, Kenneth Hess and Ken Aldape

      Article first published online: 8 AUG 2005 | DOI: 10.1002/cncr.21338

      The authors sought to determine whether histology was an equivalent or superior predictor of outcome compared with 1p/19q status in 131 patients with anaplastic oligodendroglial (AO) tumors. The results suggested that, in addition to 1p/19q status, histologic features contribute information to the prediction of outcome in patients with AO.

    2. You have free access to this content
      Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma (pages 1478–1486)

      David A. Reardon, Jennifer A. Quinn, Jeremy N. Rich, Annick Desjardins, James Vredenburgh, Sridharan Gururangan, Sith Sathornsumetee, Michael Badruddoja, Roger McLendon, James Provenzale, James E. Herndon II, Jeannette M. Dowell, Jill L. Burkart, Herbert B. Newton, Allan H. Friedman and Henry S. Friedman

      Article first published online: 8 AUG 2005 | DOI: 10.1002/cncr.21316

      The current Phase I study was based on preclinical studies demonstrating that the complementary molecular interactions between DNA alkylators/methylators and topoisomerase I inhibitors induced synergistic antitumor activity. The authors demonstrated that CPT-11 can be safely administered with temozolomide at full dose level and that this regimen was associated with highly encouraging activity among patients with recurrent malignant glioma.

    3. You have free access to this content
      Caspase 8 is absent or low in many ex vivo gliomas (pages 1487–1496)

      David M. Ashley, Christopher D. Riffkin, Andrea M. Muscat, Melissa J. Knight, Andrew H. Kaye, Ulrike Novak and Christine J. Hawkins

      Article first published online: 3 AUG 2005 | DOI: 10.1002/cncr.21323

      Death ligands, such as tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), may offer therapeutic promise for current incurable malignancies like high-grade glioma. Caspases 8 and 10 are required for death ligand signaling; thus, their levels may influence the sensitivity of glioma cells to agents like TRAIL. Evidence from other tumor types suggests that caspase 8 also may play a tumor suppressor role. In the current study, the authors showed that caspase 8 and caspase 10 frequently were low or absent in ex vivo gliomas, perhaps restricting the efficacy of death ligands as therapeutic agents for glioma.

    4. Discipline

      Clinical Trials
      You have free access to this content
      Presentation and subsequent publication rates of phase I oncology clinical trials (pages 1497–1504)

      Luis H. Camacho, Jennifer Bacik, Alexander Cheung and David R. Spriggs

      Article first published online: 22 AUG 2005 | DOI: 10.1002/cncr.21337

      Underreporting of final results of Phase I oncology trials remains a serious problem. Persistent underreporting of Phase I clinical trials hinders the dissemination of information to the medical community, delays scientific progress, and may ultimately have an adverse effect on patient care. Investigators must be committed to the publication of final results in a timely manner, and journals should provide mechanisms for the rapid reporting of Phase I trials.

    5. Dermatopathology
      You have free access to this content
      Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals (pages 1505–1511)

      Alina Burgi, Stephanie Brodine, Scott Wegner, Mark Milazzo, Mark R. Wallace, Katherine Spooner, David L. Blazes, Brian K. Agan, Adam Armstrong, Susan Fraser and Nancy F. Crum

      Article first published online: 15 AUG 2005 | DOI: 10.1002/cncr.21334

      The most common non-AIDS-defining cancers among patients who were infected with the human immunodeficiency virus (HIV) were primary skin malignancies. Melanoma, basal cell and squamous cell skin carcinomas, anal carcinoma, prostate carcinoma, and Hodgkin disease occurred at higher rates among HIV-infected individuals. The implementation of screening programs for these cancers should be considered.

    6. Epidemiology
      You have free access to this content
      Consumption of vegetables and fruits and risk of ovarian carcinoma : Results from the Netherlands Cohort Study on Diet and Cancer (pages 1512–1519)

      Monique Mommers, Leo J. Schouten, R. Alexandra Goldbohm and Piet A. van den Brandt

      Article first published online: 15 AUG 2005 | DOI: 10.1002/cncr.21332

      Results from The Netherlands Cohort Study on Diet and Cancer did not support a significant association between vegetable or fruit consumption and ovarian carcinoma risk in a cohort of postmenopausal women.

    7. You have free access to this content
      Osteoporosis and rate of bone loss among postmenopausal survivors of breast cancer : Results from a subgroup in the Women's Health Initiative Observational Study (pages 1520–1530)

      Zhao Chen, Michael Maricic, Mary Pettinger, Cheryl Ritenbaugh, Ana Maria Lopez, David H. Barad, Margery Gass, Meryl S. LeBoff and Tamsen L. Bassford

      Article first published online: 18 AUG 2005 | DOI: 10.1002/cncr.21335

      Authors of this study investigated differences in bone mineral density (measured by dual-energy x-ray absorptiometry) between breast cancer survivors and a no-cancer reference group, both from a subgroup of participants in the Women's Health Initiative Observational Study.

    8. Pediatric Oncology
      You have free access to this content
      Anorexia/cachexia-related quality of life for children with cancer : Testing the psychometric properties of the pediatric functional assessment of anorexia and cachexia therapy (peds-FAACT) (pages 1531–1539)

      Jin-Shei Lai, David Cella, Amy Peterman, Joshua Barocas and Stewart Goldman

      Article first published online: 8 AUG 2005 | DOI: 10.1002/cncr.21315

      The Pediatric Functional Assessment of Anorexia and Cachexia Therapy demonstrated good psychometric properties, differentiated patients with different functional performance status, and was determined to be a useful tool for future clinical trials.

    9. Psychological Oncology
      You have free access to this content
      Psychological responses to cancer recurrence : A controlled prospective study (pages 1540–1547)

      Barbara L. Andersen, Charles L. Shapiro, William B. Farrar, Timothy Crespin and Sharla Wells-DiGregorio

      Article first published online: 23 AUG 2005 | DOI: 10.1002/cncr.21309

      A controlled, prospective study of patients' responses to cancer recurrence indicated that patients' stress at diagnosis is cancer specific. News of cancer recurrence did not result in diffuse emotional distress and quality of life disruption, underscoring the resilience of patients at this challenging time.

    10. Symptom Control and Palliative Care
      You have free access to this content
      Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy (pages 1548–1555)

      Jørn Herrstedt, Hyman B. Muss, David G. Warr, Paul J. Hesketh, Peter D. Eisenberg, Harry Raftopoulos, Steven M. Grunberg, Munir Gabriel, Anthony Rodgers, Carolyn M. Hustad, Kevin J. Horgan, Franck Skobieranda and on behalf of the Aprepitant Moderately Emetogenic Chemotherapy Study Group

      Article first published online: 15 AUG 2005 | DOI: 10.1002/cncr.21343

      An aprepitant regimen was evaluated in patients with breast carcinoma for prevention of nausea and emesis due to multiple cycles of moderately emetogenic chemotherapy. The percentage of patients who experienced a complete response in Cycle 1 and who sustained a complete response over 4 cycles of chemotherapy was greater with the aprepitant regimen than with a control regimen consisting of a 5-HT3 receptor antagonist and a corticosteroid.

  4. Correspondence

    1. Top of page
    2. Original Articles
    3. Original Article
    4. Original Articles
    5. Correspondence
    1. You have free access to this content
    2. You have free access to this content
      Author reply (page 1557)

      Joseph M. Unger, Michael LeBlanc, Ian M. Thompson Jr. and Charles A. Coltman Jr.

      Article first published online: 13 JUL 2005 | DOI: 10.1002/cncr.21345

SEARCH

SEARCH BY CITATION